IL15 has been a primary cytokine of interest in immunotherapy due to its ability to activate the main anti‐tumour cell effectors, but does not, in contrast to IL2, stimulate immune‐suppressing regulatory T cells (Treg). Here, IL15 is linked to neoplasm.